Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 38 - Medicinal preparations containing peptides
Patents for A61K 38 - Medicinal preparations containing peptides (316,240)
05/2003
05/30/2003WO2003044163A2 Antisense modulation of toll-like receptor 4 expression
05/30/2003WO2003044162A2 Genes encoding g-protein coupled receptors and methods of use therefor
05/30/2003WO2003044160A2 Novel molecules of the card related protein family and uses thereof
05/30/2003WO2003044059A1 Agonists of recombinant human histamine h3 receptor
05/30/2003WO2003044057A2 Use of obg3 for promoting central nervous system remyelination
05/30/2003WO2003044056A2 Chemically-modified human growth hormone conjugates
05/30/2003WO2003044053A2 Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells
05/30/2003WO2003044049A1 Antimicrobial polypeptides from pseudoplectania nigrella
05/30/2003WO2003044045A2 Peptides promoting cell adherence, growth and secretion
05/30/2003WO2003044044A1 Novel peptide having angiotensin convertase inhibitory effect
05/30/2003WO2003044041A2 Alpha-fetoprotein peptides and uses for imaging
05/30/2003WO2003044040A2 Alpha-fetoprotein peptides and uses thereof
05/30/2003WO2003043986A1 Polypeptides of moraxella (branhamella) catarrhalis
05/30/2003WO2003043981A1 2-(3-sulfonylamino-2-oxopyrrolidin-1-yl)propanamides as factor xa inhibitors
05/30/2003WO2003043673A1 Device having osteoinductive and osteoconductive properties
05/30/2003WO2003043669A1 Composition and method for treatment of wounds
05/30/2003WO2003043657A1 Topical delivery of codrugs
05/30/2003WO2003043656A1 Drug for preventing vascular restenosis and instrument to be embedded in vessel coated with the drug
05/30/2003WO2003043653A1 Animal treatment
05/30/2003WO2003043652A2 The use of leptin in fertility
05/30/2003WO2003043651A1 Drug mobilizing pluripotent stem cells from tissue into peripheral blood
05/30/2003WO2003043650A1 Use of fk506 and analogues for treating allergic diseases
05/30/2003WO2003043649A1 Removal promoters and inhibitor for apoptosis cells in vivo
05/30/2003WO2003043648A2 Sfcyr iib or sfcyr iii for the treatment of auto-immune diseases
05/30/2003WO2003043647A2 A plant extract active as an immunostimulating agent
05/30/2003WO2003043631A2 Method for identification of tumor targeting enzymes
05/30/2003WO2003043624A1 Dual inhibitors of adipocyte fatty acid binding protein and keratinocyte fatty acid binding protein
05/30/2003WO2003043622A1 Substituted bicyclo[3.3.1]nonan-2,4,9-triones as pharmaceutical active ingredients
05/30/2003WO2003043586A2 Compositions for sustained action product delivery
05/30/2003WO2003043583A2 Treatment of immunological disorders using anti-cd30 antibodies
05/30/2003WO2003043580A2 Methods for identifying and validating potential drug targets
05/30/2003WO2003043576A2 Flowable osteogenic and chondrogenic compositions
05/30/2003WO2003043574A2 Pharmaceutical compositions in particulate form
05/30/2003WO2003043518A2 Methods and products for oral care
05/30/2003WO2003043486A2 Matrix for the production of tissue engineered ligaments, tendons and other tissue
05/30/2003WO2003043438A1 Oilseed processing
05/30/2003WO2003032728A3 Methods for preventing or reversing asthma and compositions useful therefor
05/30/2003WO2003026691A3 Use of hmgb1 for the activation of dendritic cells
05/30/2003WO2003016917A3 Sodium channel regulators and modulators
05/30/2003WO2003012123A3 Antisense modulation of dual specific phosphatase 9 expression
05/30/2003WO2003010141A3 Hepatitis c virus polymerase inhibitors with a heterobicyclic structure
05/30/2003WO2003008448A3 Novel human proton-gated channels
05/30/2003WO2003008007A3 Device for regeneration of articular cartilage and other tissue
05/30/2003WO2003005034A3 Processes for identifying therapeutic agents useful in treating diseases involving fzd4 gene
05/30/2003WO2003004650A3 Group b streptococcus antigens and corresponding dna fragments
05/30/2003WO2003004045A3 Methods for identifying therapeutic agents for treating diseases involving wnt polypeptides and wnt receptors
05/30/2003WO2003003976A3 Compositions for removing human cerumen
05/30/2003WO2003001204A3 Type 1 diabetes diagnostics and therapeutics
05/30/2003WO2003000111A3 Human ugrp (uteroglobin-related protein) 1 promoter and its use
05/30/2003WO2002100898A3 Polypeptide having an activity to support proliferation or survival of hematopoietic stem cell and hematopoietic progenitor cell, and dna coding for the same
05/30/2003WO2002096952A3 Conjugate of a transport protein and a protein for modulation of notch signalling
05/30/2003WO2002095029A3 Nucleic acid and protein sequences of bovine epidermal growth factor
05/30/2003WO2002089829A3 Polymorphism in the eosinophil cationic protein (ecp) used in the treatment of e.g. cancer
05/30/2003WO2002077029A3 Cd19-specific redirected immune cells
05/30/2003WO2002076501A3 Blood cell production via activation of the hemoglobin scavenger receptor
05/30/2003WO2002072621A3 Cyclohexapeptide having antimicrobial activity
05/30/2003WO2002067967A3 Method of treating rhinitis or sinusitis
05/30/2003WO2002066040A3 Sensitization of chemotherapeutic agent resistant neoplastic cells with reovirus
05/30/2003WO2002064621A3 Histidine proline rich glycoprotein (hprg) as an anti-angiogenic and anti-tumor agent
05/30/2003WO2002064132A3 Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability
05/30/2003WO2002058624A3 In situ generation allicin for the treatment of cancer and infectious diseases
05/30/2003WO2002057314A3 Prevention and treatment of hcv infection employing antibodies directed against conformational epitopes
05/30/2003WO2002051868A3 Methods and materials relating to stem cell growth factor-like polypeptides and polynucleotides
05/30/2003WO2002048372A3 Target enzymes
05/30/2003WO2002047717A9 Targeted enzyme prodrug therapy
05/30/2003WO2002036816A3 Method of determining susceptibility to diseases
05/30/2003WO2002036148A3 Use of death receptor ligands or rip to initiate the non-caspase-dependent cell death and compounds for inhibition of the non-caspase-dependent cell death
05/30/2003WO2002031025A9 Biodegradable poly(beta-amino esters) and uses thereof
05/30/2003WO2002030443A3 Regulation of human skin healing
05/30/2003WO2002020790A9 Parietaria judaica ns-ltp antigen variants, uses thereof and compositions comprising them
05/30/2003WO2002018425A3 '47324', a novel g-protein and uses therefor
05/30/2003WO2001087922A3 Derivatisation of proteins in aqueous solution
05/30/2003WO2001075075A3 Human tyrosine phosphatase-like enzymes
05/30/2003WO2001052874A9 Intra-tumoral administration of il-12 encoding nucleic acid molecules
05/30/2003CA2506616A1 Substituted bicyclo[3.3.1]nonan-2,4,9-triones as pharmaceutical active ingredients
05/30/2003CA2492536A1 Postsynaptic proteins
05/30/2003CA2468170A1 Method for identification of tumor targeting enzymes
05/30/2003CA2468107A1 Methods for identifying and validating potential drug targets
05/30/2003CA2467927A1 Antimicrobial polypeptides from pseudoplectania nigrella
05/30/2003CA2467908A1 Mfg-e8-l regulates phagocytic removal of apoptotic cells by macrophages
05/30/2003CA2467756A1 Alpha-fetoprotein peptides and uses thereof
05/30/2003CA2467747A1 Methods and products for oral care
05/30/2003CA2467731A1 Chemically-modified human growth hormone conjugates
05/30/2003CA2467559A1 Topical delivery of codrugs
05/30/2003CA2467557A1 Agent which mobilizes multipotential stem cells from tissues to peripheral blood
05/30/2003CA2467536A1 The use of leptin in fertility
05/30/2003CA2467246A1 Composition and method for treatment of wounds
05/30/2003CA2467242A1 Treatment of immunological disorders using anti-cd30 antibodies
05/30/2003CA2467206A1 Genes encoding g-protein coupled receptors and methods of use therefor
05/30/2003CA2467195A1 Matrix for the production of tissue engineered ligaments, tendons and other tissue
05/30/2003CA2467181A1 Peptides promoting cell adherence, growth and secretion
05/30/2003CA2467104A1 A plant extract active as an immunostimulating agent
05/30/2003CA2467053A1 Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells
05/30/2003CA2466982A1 Pharmaceutical compositions in particulate form
05/30/2003CA2465779A1 Compositions for sustained action product delivery
05/30/2003CA2464957A1 Polypeptides of moraxella (branhamella) catarrhalis
05/30/2003CA2464542A1 Composition comprising and method of using angiopoietin-like protein 3 angptl3
05/30/2003CA2463790A1 Cyclic amp phosphodiesterase 4d7 isoforms and methods of use
05/30/2003CA2407302A1 Genes transfection into bony tissues
05/29/2003US20030101480 Artificial chromosomes, uses therof and methods for preparing artificial chromosomes
1 ... 1836 1837 1838 1839 1840 1841 1842 1843 1844 1845 1846 1847 1848 1849 1850 1851 1852 1853 1854 1855 1856 ... 3163